Table 2.
Human Papillomavirus Genotypes Distribution in Genital Infection and Cervical Cancer in Iran’s Neighbouring Countries and Persian Gulf Area
| Author/Year | Region | HPV Detection Method | Number /Type of Study | HPV Positive/ HPV Genotypes /Co infection |
|---|---|---|---|---|
| Raza et al.,2010 [36] | Pakistn | Home Brew PCR GP5/GP6 & Reverse Line Blot Hybridization | 899/ Routine Checkups & Abnormal Cytology | 2.78% / HPV 16,18,45,56,33,59 / Not Mentioned |
| Siddiqa et al.,2014 [37] | Pakistn | Home Brew PCR GP5/GP6 & Duplex PCR 16&18 | 77/ Cervical Cancer | 53.24% / HPV16,18 / Not Mentioned |
| Akbar et al., 2015 [38] | Pakistn | Home Brew PCR GP5/GP6 & Duplex PCR 16&18 | 200/Routine Checkups | 2% / HPV 16,18 / Not Mentioned |
| Shahid et al., 2015 [39] | Pakistn | Home Brew PCR GP5/GP6 & Duplex PCR 16&18 | 160/Routine Checkups | 1.87% / HPV16 / Not Mentioned |
| Darnel et al., 2010 [40] | Syria | Home Brew Specific PCR (E7) | 44/ FFPE Cervical Cancer | 95.45% / HPV 33,16,18,45,52,58,35,51,31 / Not Mentioned |
| Banna et al., 2014 [41] | UAE | Home Brew& mix of 13 primers 16,18,31,33,35,39,45,51,52,56,58,59,68 |
50/ Neg. Pap Smear Tests | 10% / Any of 13 types / Not Mentioned |
| Bensumaidea et al.,2014 [42] | Yemen | Immunohistochemistry & HPV16/18 kit ( Sacace-Biotechnologies) |
84/ Cervical Cancer | 100% / HPV 16,18 / Not Mentioned |
| Ahmed et al., 2015 [43] |
Yemen | HPV 31,33,35,39,45 ( Sacace-Biotechnologies) |
200/ FFPE Cervial Cancer & Benign Tissue | 24%/HPV 31,45,33,35,39/ 1% |
| Haiija et al.,2006 [44] | Bahran | Home Brew PCR & RFLP | 100/ Routine Checkups | 11% / HPV 16,18,45,62,53 / Not mentioned |
| Moosa et al.,2014 [45] | Bahran | LiPA | 571/ Routine Checkups | 9.8% / HPV52,16,31,51,6,70,74 / 2.62% |
| Fadhil et al., 2014 [46] | Iraq | Genoaaray primer-based PCR 21 HR & LR types |
188/ Cervical Dysplasia | 99.91% (82.35% HR-types & 17.56% LR types) / 27.94% |
| Al-Awadhi et al., 2011 [47] | Kuwait | Home Brew PCR GP5/GP6, MY09/MY11 & Sequencing | 3011/ Routine Checkups | 2.3% / HPV11,81,61,53,54, 90,31,73,84,106, 33,56,58,67,70,82,83,10 / Not Mentioned |
| Al-Tahani et al., 2010 [48] | Qatar | RT-PCR (E1–E2 region) Sacace Biotechnologies, Italy |
95% / Abnormal Screening | 64% / HPV 16,52,56 / 34.4% |
| Elmi et al., 2012 [49] | Qatar | Real Time PCR Sacace Biotechnology, Italy |
1100/ Routine Checkups | 11.36%/15 HPV Genotypes Detected/ Not Mentioned |
| Bansal et al., 2014 [50] | Qatar | Real Time PCR Sacace Biotechnology, Italy |
3008/ Routine Checkups | 11.8% / HPV 81,11,16,18,56 / 0.93% |
| Al-Sbeih et al., 2011 [51] | Saudi Arabia | Linear Array Detection Kit (LA DK) (Roche) (37 genotypes) | 100/ Cervical Cancer | 89% / HPV 16,18,31,39,45,51,59,73,6,64,70 / 5.5% |
| AlBadawi et al.,2011 [52] |
Saudi Arabia | Home Brew PCR GP5/GP6, MY09/MY11 & Sequencing & Reverse Line Blot Hybr (RLB) | 90/ Cervical Cancer | 95.55% /HPV 16,18,45,33,31,52,53,58,59,66 /18.88% |
| Al-Sbeih et al., 2013 [53] |
Saudi Arabia | Linear Array HPV Genotyping (Roche) (37 genotypes) |
318/ Cervical Cancer | 82% / HPV 16,31,18,45,73,32,70,592,59 / 2.2% |
| Bondji et al., 2013 [54] | Saudi Arabia | Hybrid Capture II | 485/ Routine Checkups | 5.6% / Not Mentioned |
| Turki et al., 2013 [55] | Saudi Arabia | Multiplex PCR Plus BiofilmChip Hybridization Assay (26 types) | 40/ Abnormal Screening | 42.5 % / HPV 16,18,45 / 0% |
| Al-Obaid et al., 2014 [56] | Saudi Arabia | LiPA | 417/ Routine Checkups | 6.95% / HPV68/73,18,16,31,51,52,39,56,58,6 ,42,54,11,40,70,74 / 0.95% |
| Al-Ahdal et al., 2014 [57] | Saudi Arabia | Reverse Line Blot Hybridization | 519/ Routine Checkups & Abnormal Cytology | 31.6% / HPV16,18,11/ Not Mentioned |